# EDGAR Filing Document

**Accession Number:** 0000877860
**File Stem:** 0000877860-23-000017
**Filing Date:** 2023-2
**Character Count:** 6965
**Document Hash:** 8d475d70b84b2a47bc35b65c854fc9c6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000877860-23-000017.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0000877860-23-000017

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20230221

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NATIONAL HEALTH INVESTORS INC
- **CENTRAL INDEX KEY:** 0000877860
- **STANDARD INDUSTRIAL CLASSIFICATION:** REAL ESTATE INVESTMENT TRUSTS [6798]
- **IRS NUMBER:** 621470956
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-10822
- **FILM NUMBER:** 23648500

**BUSINESS ADDRESS:**
- **STREET 1:** 222 ROBERT ROSE DRIVE
- **CITY:** MURFREESBORO
- **STATE:** TN
- **ZIP:** 37129
- **BUSINESS PHONE:** 6158909100

**MAIL ADDRESS:**
- **STREET 1:** 222 ROBERT ROSE DRIVE
- **CITY:** MURFREESBORO
- **STATE:** TN
- **ZIP:** 37129

?xml version="1.0" ? nhi-20230221

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): February 21, 2023

**<u>National Health Investors Inc</u>**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| <u>Maryland</u> | 001-10822 | <u>62-1470956</u> |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

222 Robert Rose Drive

<u>Murfreesboro, TN 37129</u> 

(Address of principal executive offices)

<u>(615) 890-9100</u> 

(Registrant's telephone number, including area code)

<u>Not Applicable</u>

(Former name, former address and former fiscal year,

if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.01 par value | NHI | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

Item 7.01. Regulation FD Disclosure.

The Company is furnishing its Supplemental Information for the year ended December 31, 2022, which is also contained on its website (www.nhireit.com). See Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

Exhibit Index

---

| | |
|:---|:---|
| **Number** | **Exhibit** |
| 99.1 | <u>[Supplemental Information for the](item991-q42022supplemental.htm)[year](item991-q42022supplemental.htm)[ended](item991-q42022supplemental.htm)[December](item991-q42022supplemental.htm)[3](item991-q42022supplemental.htm)[1](item991-q42022supplemental.htm)[, 2022, dated](item991-q42022supplemental.htm)[February](item991-q42022supplemental.htm)[21](item991-q42022supplemental.htm)[, 202](item991-q42022supplemental.htm)[3](item991-q42022supplemental.htm)</u> |

---

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

National Health Investors, Inc.

By: <u>/s/ John L. Spaid</u>

Name: John L. Spaid

Title: Chief Financial Officer

Date: February 21, 2023

## Exhibit 99.1

![q42022supplemental_lowres1.jpg](q42022supplemental_lowres1.jpg)

------

![q42022supplemental_lowres1n.jpg](q42022supplemental_lowres1n.jpg)

------

![q42022supplemental_lowres1j.jpg](q42022supplemental_lowres1j.jpg)

------

![q42022supplemental_lowres1y.jpg](q42022supplemental_lowres1y.jpg)

------

![q42022supplemental_lowres1o.jpg](q42022supplemental_lowres1o.jpg)

------

![q42022supplemental_lowres1q.jpg](q42022supplemental_lowres1q.jpg)

------

![q42022supplemental_lowres1a.jpg](q42022supplemental_lowres1a.jpg)

------

![q42022supplemental_lowres1h.jpg](q42022supplemental_lowres1h.jpg)

------

![q42022supplemental_lowres1i.jpg](q42022supplemental_lowres1i.jpg)

------

![q42022supplemental_lowres1c.jpg](q42022supplemental_lowres1c.jpg)

------

![q42022supplemental_lowres1d.jpg](q42022supplemental_lowres1d.jpg)

------

![q42022supplemental_lowres1z.jpg](q42022supplemental_lowres1z.jpg)

------

![q42022supplemental_lowres1u.jpg](q42022supplemental_lowres1u.jpg)

------

![q42022supplemental_lowres11.jpg](q42022supplemental_lowres11.jpg)

------

![q42022supplemental_lowres1v.jpg](q42022supplemental_lowres1v.jpg)

------

![q42022supplemental_lowres1r.jpg](q42022supplemental_lowres1r.jpg)

------

![q42022supplemental_lowres1f.jpg](q42022supplemental_lowres1f.jpg)

------

![q42022supplemental_lowres1p.jpg](q42022supplemental_lowres1p.jpg)

------

![q42022supplemental_lowres1w.jpg](q42022supplemental_lowres1w.jpg)

------

![q42022supplemental_lowres1g.jpg](q42022supplemental_lowres1g.jpg)

------

![q42022supplemental_lowres1l.jpg](q42022supplemental_lowres1l.jpg)

------

![q42022supplemental_lowres1e.jpg](q42022supplemental_lowres1e.jpg)

------

![q42022supplemental_lowres1k.jpg](q42022supplemental_lowres1k.jpg)

------

![q42022supplemental_lowres1t.jpg](q42022supplemental_lowres1t.jpg)

------

![q42022supplemental_lowres1s.jpg](q42022supplemental_lowres1s.jpg)

------

![q42022supplemental_lowres1b.jpg](q42022supplemental_lowres1b.jpg)

------

![q42022supplemental_lowres1x.jpg](q42022supplemental_lowres1x.jpg)

------

![q42022supplemental_lowres1m.jpg](q42022supplemental_lowres1m.jpg)

<br>